Navigation Links
Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinson's Research Award for Work on PD-implicated Protein LRRK2
Date:7/29/2008

LA JOLLA, Calif., July 29 /PRNewswire/ -- Zenobia Therapeutics, Inc. (Zenobia) announced today that it has received a Therapeutics Development Initiative award from The Michael J. Fox Foundation for Parkinson's Research. The program targets industry-based research with potential to fundamentally alter the course of Parkinson's disease (PD) treatment. In collaboration with Dr. Christopher Ross of Johns Hopkins University, Zenobia will discover and develop compounds that block the activity of LRRK2, a protein that is believed to be overactive in PD patients. The goal is to preserve brain function by stopping the effects of the overactivity. If successful, the work could lead to a neuroprotective treatment for PD with potential to slow or stop the course of the disease -- something no currently available therapy has been proven to do. Current treatments alleviate the symptoms but do not attack the underlying disease, or alter its course.

Zenobia will use its fragment-based lead discovery (FBLD) expertise to discover compounds that bind to LRRK2. FBLD is a proven drug discovery approach where fragments of drugs are screened for ability to bind to a target. Fragments will be visualized bound to LRRK2 and evolved into compounds that block its activity. These compounds will be tested for their ability to protect neurons in cell culture, and to reverse effects of the overactive protein in animal models. "I believe Zenobia's methods represent a unique and tremendously exciting approach to drug discovery," said Christopher A. Ross, M.D., Ph.D, Professor of Psychiatry, Neurology and Neuroscience at Johns Hopkins University, and chair of Zenobia's Scientific Advisory Board. "The fragment-based screening method has the potential to identify and develop novel compounds not present in the libraries of large pharmaceutical companies. It also is more likely to identify small ligands with a better chance of good penetration into the brain, making it especially suitable for targeting neurological and psychiatric diseases."

Dr. Ross is a leader in neurodegenerative disease research; he helped to define LRRK2 as a PD target, and is an expert in its biology. As part of the collaboration, Zenobia will have access to cell assays and animal models developed by the Ross laboratory. "We are very excited to combine our expertise in fragment-based lead discovery with the expertise of Dr. Ross," said Vicki Nienaber, Ph.D., President and Founder of Zenobia. "We are a long way from a cure, but we took the first step this week with the help of the Michael J. Fox foundation."

Zenobia's research is focused on debilitating, limited-population diseases that have no cure. Zenobia combines fragment-based lead discovery with the expertise of biologists and clinicians to find treatments for illnesses such as Parkinson's disease, Huntington's disease and Muscular Dystrophy. In the future, Zenobia will focus on psychiatric diseases in parallel with increased understanding of the biology of these diseases.

For additional information on Zenobia Therapeutics, Inc., contact Dr. Vicki Nienaber at vicki@zenobiatherapeutics.com or visit http://www.zenobiatherapeutics.com.


'/>"/>
SOURCE Zenobia Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
2. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
3. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
4. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
5. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
6. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
7. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
8. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
9. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
10. Cell Therapeutics, Inc. (CTI) to Report 2008 First Quarter and Financial Results on May 8
11. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2017)... , ... July 18, 2017 , ... ... Framework, and has released the first phase of the Allotrope Framework for commercial ... Practices Awards were created to “not only elevate the critical role of information ...
(Date:7/17/2017)... ... July 17, 2017 , ... OHAUS Corporation, a leading worldwide ... its new line of Heavy-Duty Orbital Shakers today. , Eight New Models Available, ... laboratory applications. These shakers are ideal for load capacities from 35 to ...
(Date:7/16/2017)... ... July 16, 2017 , ... ... instruments announced the launch of its new line of Rocking and Waving Shakers ... waving shaker models (both analog and digital) for laboratory applications in a variety ...
(Date:7/14/2017)... ... July 13, 2017 , ... LGC ... kit has received US FDA 510 (k) clearance for use on Siemens Sysmex® ... D-Dimer. Each VALIDATE® D-Dimer kit, prepared using the CLSI EP06-A “equal delta” sample ...
Breaking Biology Technology:
(Date:6/30/2017)... , June 30, 2017 Today, ... developer and supplier of face and eye tracking ... Featured Product provider program. "Artificial ... innovative way to monitor a driver,s attentiveness levels ... from being able to detect fatigue and prevent ...
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ... of online age and identity verification solutions, announced today ... Identity Conference 2017, May 15 thru May 17, 2017, ... Building and International Trade Center. Identity ... globe and in today,s quickly evolving digital world, defining ...
(Date:4/19/2017)... York , April 19, 2017 ... as its vendor landscape is marked by the presence ... market is however held by five major players - ... Together these companies accounted for nearly 61% of the ... the leading companies in the global military biometrics market ...
Breaking Biology News(10 mins):